Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

NCT04131309 is registered in ClinicalTrials.gov with Stichting European Myeloma Network as lead sponsor.

NCT NCT04131309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04131309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis
Lead sponsor
Stichting European Myeloma Network
Phase
Phase 2
Overall status
Completed
Start date
September 23, 2019
Completion date
January 27, 2025
Enrollment
40 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

light chain (al) amyloidosis, stage 3b